‘aioaiz021 DDrig relieves persistent daydraaming, fatigue, and brain sluggishness in adults wit ADHO ~ ScienceDaily ScienceDaily Your source for the latest research news Science News from research organizations Drug relieves persistent daydreaming, fatigue, and brain sluggishness in adults with ADHD Date: June 29, 2021 Source: NYU Langone Health / NYU Grossman School of Medicine Summary: Tests of a drug known to stimulate brain activity have shown early success in reducing symptoms of sluggish cognitive tempo in 38 men and women with attention deficit hyperactivity disorder (ADHD.) Shar: f W P in FULL STORY Tests of a drug known to stimulate brain activity have shown early success in reducing symptoms of sluggish cognitive tempo in 38 men and women with attention deficit hyperactivity disorder (ADHD.) A collection of symptoms including persistent dreaminess, fatigue, and slow-working speed, sluggish cognitive tempo has been a subject of debate over whether itis part of, or separate from, ADHD. Researchers at NYU Grossman School of Medicine and Icahn School of Medicine at Mount Sinai who led the study say the stimulant lisdexamfetamine (sold as Vyvanse) reduced by 30 percent self-reported symptoms of sluggish cognitive tempo. It also lowered by over 40 percent symptoms of ADHD and significantly corrected deficits in executive brain function, with fewer episodes of procrastination, improvements in keeping things in mind, and strengthened prioritization skill. Publishing in the Journal of Clinical Psychiatry online June 29, the study also showed that one-quarter of the overall improvements in sluggish cognitive tempo, such as feelings of boredom, trouble staying alert, and signs of confusion, were due to improvements in symptoms of ADHD. The team interpreted that outcome to mean that decreases in ADHD-related incidents of physical restlessness, behaving impulsively, and/or moments of not paying attention were linked to some but not all of the improvements in sluggish cognitive tempo. “Our study provides further evidence that sluggish cognitive tempo may be distinct from attention deficit hyperactivity disorder and that the stimulant lisdexamfetamine treats both conditions in adults, and when they ‘occur together,” says lead study investigator and psychiatrist Lenard Adler, MD. Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD. The NYU Langone-Mount Sinai team's findings, he adds, are the first to show that such treatments also work in adults, hitpsslwwn.sciencedally.com/releases/2021108/210620134327 him 4‘4108/2021 Dug relieves persistent daydreaming, fatigue, and brain luggishness in aduls wih ADHD ~ ScieneeDatiy A professor in the Departments of Psychiatry and Child and Adolescent Psychiatry at NYU Langone, Adler ‘says sluggish cognitive tempo is likely a subset of symptoms commonly seen in some patients with ADHD and other psychiatric disorders. However, it remains unclear if sluggish cognitive tempo is a distinct psychiatric condition on its own and if stimulant medications will improve sluggish cognitive tempo in patients without ‘ADHD. ‘Some specialists have been seeking to qualify sluggish cognitive tempo as distinct, but critics say more research is needed to settle the question. “These findings highlight the importance of assessing symptoms of sluggish cognitive tempo and executive brain function in patients when they are initially diagnosed with ADHD,” says Adler. For the study, funded by the drug manufacturer, Takeda Pharmaceuticals of Cambridge, Mass., several dozen volunteer participants received daily doses of either lisdexamfetamine or a placebo sugar pill for one month. Researchers then carefully tracked their psychiatric health on a weekly basis through standardized tests for signs and symptoms of sluggish cognitive tempo, ADHD, as well as other measures of brain function, Study participants then switched roles: The one-half who had been taking the placebo started taking daily doses of lisdexamfetamine, while the other half who had been on the drug during the study's first phase started taking the placebo. ‘Adler has received grant andlor research support from Sunovion Pharmaceuticals, Enymotec, Shire Pharmaceuticals (now part of Takeda), Otsuka, and Lundbeck. He has also served as a paid consultant to these companies, in addition to Bracket, SUNY, the National Football League, and Major League Baseball. He has also received royalty payments since 2004 from NYU for adult ADHD diagnostic and training materials, All of these relationships are being managed in accordance with the policies and procedures of NYU Langone. Story Source: Materials provided by NYU Langone Health / NYU Grossman School of Medicine. Note: Content may be edited for style and length. Journal Reference: 1, Lenard A. Adler et al. A Placebo-Controlled Trial of Lisdexamfetamine in the Treatment of Comorbid Sluggish Cognitive Tempo and Adult ADHD. Journal of Clinical Psychiatry, 2021 [abstract] This P Gite This Page: MLA APA Chicago NYU Langone Health / NYU Grossman School of Medicine. "Drug relieves persistent daydreaming, fatigue, and brain sluggishness in adults with ADHD." ScienceDaily. ScienceDaily, 29 June 2021 RELATED STORIES Therapy Dogs Effective in Reducing Symptoms of ADHD, Study Finds July 18, 2018 — Researchers have found therapy dogs to be effective in reducing the symptoms of attention deficithhyperactivity disorder (ADHD) in ... Younger Aged Children With Symptoms of ADHD Have Reduced Brain Size hitpsslwwn.sciencedally.com/releases/2021108/210620134327 him 28‘4108/2021 Dug relieves persistent daydreaming, fatigue, and brain luggishness in aduls wih ADHD ~ ScieresDatiy Mar. 26, 2018 — Children as young as four years old with symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) showed reduced brain volumes in regions essential for behavioral control, according to anew... Brain Imaging Reveals ADHD as a Collection of Different Disorders. Nov. 7, 2017 — Researchers have found that patients with different types of attention-deficitfhyperactivity disorder (ADHD) have impairments in unique brain systems, indicating that there may not be a Cognitive-Behavioral Therapy Particularly Efficient in Treating ADHS in Adults ‘Aug. 23, 2017 — Cognitive-behavioral therapy (CBT) group training was shown to achieve the same results as neurofeedback training in treating attention-deficit hyperactivity disorder (ADHD). Both methods led to a FROM AROUND THE WEB ScienceDaily shares links with sites in the TrendMD network and eams revenue from third-party advertisers, where indicated. Expert discusses nonmedical simulant use in college-age adults Healio Lisdexamfetamine improves outcomes of adults Healio Steps PCPs can take to address nonmedical Healio julant use in college-aged adults Lisdexamfetamine safe, effective for treating ADHD symptoms in adolescents Healio Lisdexamfetamine dimesylate effective with chronic fatigue syndrome, cognition and pain Healio Researchers develop updated adult ADHD screening scale Healio Tepotinib Yields High Partial Response Rates in NSCLC With MET Alterations Cardiology Advisor, 2020 Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors Cardiology Advisor, 2020 Powered by | consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more Yes No Free Subscriptions hitpsslwwu.sciencedally.com/releases/2021108/210820134327 him aia‘aioaiz021 DDrg relieves persistent daydraaming, fatigue, and brain sluggishness in adults with ADHO ~ SclanceDally Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader: © Email Newsletters RSS Feeds Follow Us Keep up to date with the latest news from ScienceDaily via social networks: Facebook ¥ Twitter in Linkedin Have Feedback? Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions? ® Leave Feedback %& Contact Us ‘About This Site | Staff | Reviews | Contribute | Advertise | Privacy Policy | Editorial Policy | Terms of Use Copyright 2021 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners. Content on this website is for information only. It is not intended to provide medical or other professional advice. Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners. Financial support for ScienceDaily comes from advertisements and referral programs, where indicated. — GDPR: Privacy Settings — hitpsslwwu.sciencedally.com/releases/2021108/210820134327 him 4a